Reprogramming
the
immunosuppressive
tumor
microenvironment
by
modulating
macrophages
holds
great
promise
in
immunotherapy.
As
a
class
of
professional
phagocytes
and
antigen-presenting
cells
innate
immune
system,
can
not
only
directly
engulf
clear
cells,
but
also
play
roles
presenting
tumor-specific
antigen
to
initiate
adaptive
immunity.
However,
tumor-associated
(TAMs)
usually
display
tumor-supportive
M2
phenotype
rather
than
anti-tumor
M1
phenotype.
They
support
escape
immunological
surveillance,
aggravate
progression,
impede
T
cell
Although
many
TAMs-modulating
agents
have
shown
success
therapy
multiple
tumors,
they
face
enormous
challenges
including
poor
accumulation
off-target
side
effects.
An
alternative
solution
is
use
advanced
nanostructures,
which
deliver
augment
therapeutic
efficacy,
serve
as
modulators
TAMs.
Another
important
strategy
exploitation
macrophage-derived
components
tumor-targeting
delivery
vehicles.
Herein,
we
summarize
recent
advances
targeting
engineering
for
immunotherapy,
(1)
direct
indirect
effects
on
augmentation
immunotherapy
(2)
strategies
macrophage-based
drug
carriers.
The
existing
perspectives
immunotherapies
are
highlighted.
Signal Transduction and Targeted Therapy,
Год журнала:
2022,
Номер
7(1)
Опубликована: Июнь 20, 2022
Abstract
In
recent
years,
immunotherapy
represented
by
immune
checkpoint
inhibitors
(ICIs)
has
led
to
unprecedented
breakthroughs
in
cancer
treatment.
However,
the
fact
that
many
tumors
respond
poorly
or
even
not
ICIs,
partly
caused
absence
of
tumor-infiltrating
lymphocytes
(TILs),
significantly
limits
application
ICIs.
Converting
these
“cold”
into
“hot”
may
ICIs
is
an
unsolved
question
immunotherapy.
Since
it
a
general
characteristic
cancers
resist
apoptosis,
induction
non-apoptotic
regulated
cell
death
(RCD)
emerging
as
new
treatment
strategy.
Recently,
several
studies
have
revealed
interaction
between
RCD
and
antitumor
immunity.
Specifically,
autophagy,
ferroptosis,
pyroptosis,
necroptosis
exhibit
synergistic
responses
while
possibly
exerting
inhibitory
effects
on
responses.
Thus,
targeted
therapies
(inducers
inhibitors)
against
combination
with
exert
potent
activity,
resistant
This
review
summarizes
multilevel
relationship
immunity
RCD,
including
necroptosis,
potential
targeting
improve
efficacy
malignancy.
Abstract
The
use
of
nanotechnology
has
the
potential
to
revolutionize
detection
and
treatment
cancer.
Developments
in
protein
engineering
materials
science
have
led
emergence
new
nanoscale
targeting
techniques,
which
offer
renewed
hope
for
cancer
patients.
While
several
nanocarriers
medicinal
purposes
been
approved
human
trials,
only
a
few
authorized
clinical
cells.
In
this
review,
we
analyze
some
formulations
discuss
challenges
translating
findings
from
lab
clinic.
This
study
highlights
various
compounds
that
can
be
used
selective
tumor
inherent
difficulties
therapy.
Nanotechnology
provides
promising
platform
improving
future,
but
further
research
is
needed
overcome
current
limitations
translation.
Graphical
Cancer Communications,
Год журнала:
2022,
Номер
42(2), С. 88 - 116
Опубликована: Фев. 1, 2022
Abstract
The
hallmark
of
tumorigenesis
is
the
successful
circumvention
cell
death
regulation
for
achieving
unlimited
replication
and
immortality.
Ferroptosis
a
newly
identified
type
dependent
on
lipid
peroxidation
which
differs
from
classical
programmed
in
terms
morphology,
physiology
biochemistry.
broad
spectrum
injury
tumor
tolerance
are
main
reasons
radiotherapy
chemotherapy
failure.
effective
rate
immunotherapy
as
new
treatment
method
less
than
30%.
can
be
seen
radiotherapy,
chemotherapy,
immunotherapy;
therefore,
ferroptosis
activation
may
potential
strategy
to
overcome
drug
resistance
mechanism
traditional
cancer
treatments.
In
this
review,
characteristics
causes
by
briefly
described.
addition,
three
metabolic
regulations
its
crosstalk
with
signaling
pathways
summarized.
Collectively,
these
findings
suggest
vital
role
based
interaction
immunotherapy,
thus,
indicating
remarkable
treatment.
Cell Metabolism,
Год журнала:
2022,
Номер
35(1), С. 84 - 100.e8
Опубликована: Окт. 17, 2022
Treatment
of
triple-negative
breast
cancer
(TNBC)
remains
challenging.
Deciphering
the
orchestration
metabolic
pathways
in
regulating
ferroptosis
will
provide
new
insights
into
TNBC
therapeutic
strategies.
Here,
we
integrated
multiomics
data
our
large
cohort
(n
=
465)
to
develop
atlas.
We
discovered
that
TNBCs
had
heterogeneous
phenotypes
ferroptosis-related
metabolites
and
pathways.
The
luminal
androgen
receptor
(LAR)
subtype
was
characterized
by
upregulation
oxidized
phosphatidylethanolamines
glutathione
metabolism
(especially
GPX4),
which
allowed
utilization
GPX4
inhibitors
induce
ferroptosis.
Furthermore,
verified
inhibition
not
only
induced
tumor
but
also
enhanced
antitumor
immunity.
combination
anti-PD1
possessed
greater
efficacy
than
monotherapy.
Clinically,
higher
expression
correlated
with
lower
cytolytic
scores
worse
prognosis
immunotherapy
cohorts.
Collectively,
this
study
demonstrated
landscape
revealed
an
innovative
strategy
for
refractory
LAR
tumors.
Signal Transduction and Targeted Therapy,
Год журнала:
2023,
Номер
8(1)
Опубликована: Сен. 21, 2023
Abstract
Ferroptosis
is
an
iron-dependent
form
of
regulated
cell
death
with
distinct
characteristics,
including
altered
iron
homeostasis,
reduced
defense
against
oxidative
stress,
and
abnormal
lipid
peroxidation.
Recent
studies
have
provided
compelling
evidence
supporting
the
notion
that
ferroptosis
plays
a
key
pathogenic
role
in
many
diseases
such
as
various
cancer
types,
neurodegenerative
disease,
involving
tissue
and/or
organ
injury,
inflammatory
infectious
diseases.
Although
precise
regulatory
networks
underlie
are
largely
unknown,
particularly
respect
to
initiation
progression
diseases,
recognized
bona
fide
target
for
further
development
treatment
prevention
strategies.
Over
past
decade,
considerable
progress
has
been
made
developing
pharmacological
agonists
antagonists
these
ferroptosis-related
conditions.
Here,
we
provide
detailed
overview
our
current
knowledge
regarding
ferroptosis,
its
pathological
roles,
regulation
during
disease
progression.
Focusing
on
use
chemical
tools
preclinical
studies,
also
summarize
recent
advances
targeting
across
growing
spectrum
ferroptosis-associated
Finally,
discuss
new
challenges
opportunities
potential
strategy
treating
Immunotherapy
is
used
to
regulate
systemic
hyperactivation
or
hypoactivation
treat
various
diseases.
Biomaterial-based
immunotherapy
systems
can
improve
therapeutic
effects
through
targeted
drug
delivery,
immunoengineering,
etc.
However,
the
immunomodulatory
of
biomaterials
themselves
cannot
be
neglected.
In
this
review,
we
outline
with
functions
discovered
in
recent
years
and
their
applications
disease
treatment.
These
inflammation,
tumors,
autoimmune
diseases
by
regulating
immune
cell
function,
exerting
enzyme-like
activity,
neutralizing
cytokines,
The
prospects
challenges
biomaterial-based
modulation
are
also
discussed.
Journal of the American Chemical Society,
Год журнала:
2021,
Номер
143(38), С. 15812 - 15823
Опубликована: Сен. 2, 2021
Iron-based
nanoparticles
have
attracted
much
attention
because
of
their
ability
to
induce
ferroptosis
via
a
catalyzing
Fenton
reaction
and
further
potentiate
immunotherapy.
However,
current
iron-based
need
be
used
in
cooperation
with
other
treatments
or
applied
high
dose
for
effective
therapy
low
reactive
oxygen
species
production
efficacy.
Here,
we
synthesized
ultrasmall
single-crystal
Fe
(bcc-USINPs)
that
stayed
stable
normal
physiological
environment
but
were
highly
active
tumor
microenvironment
the
selective
acidic
etching
an
Fe3O4
shell
exposure
Fe(0)
core.
The
bcc-USINPs
could
efficiently
cell
immunogenetic
death
at
very
concentration.
Intravenous
injection
iRGD-bcc-USINPs
three
doses
1
mg/kg
effectively
suppress
growth,
promote
maturation
dendritic
cells,
trigger
adaptive
T
response.
Combined
programmed
death-ligand
(PD-L1)
immune
checkpoint
blockade
immunotherapy,
iRGD-bcc-USINP-mediated
greatly
potentiated
response
developed
strong
memory.
In
addition,
these
USINPs
quickly
renal
excreted
no
side
effects
tissues.
These
provide
simple,
safe,
effective,
selectively
tumor-responsive
delivery
system
ferroptosis-based